PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma

作     者：Chengming Liu Zhanyu Wang Qingpeng Zeng Sufei Zheng Xiaoli Feng Qi Xue Nan Sun Jie He Chengming Liu;Zhanyu Wang;Qingpeng Zeng;Sufei Zheng;Xiaoli Feng;Qi Xue;Nan Sun;Jie He

作者机构：Department of Thoracic SurgeryNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China State Key Laboratory of Molecular OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of PathologyNational Cancer Center/National Clinical Research Centerfor Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2023年第10卷第1期

页      面：48-50页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Key Basic Research Development Plan of China 国家自然科学基金 the National Key R&D Program of China 

主　　题：lung cancer metastasis 

摘      要：Small-cell lung cancer(SCLC)is a highly malignant cancer with characteristics of rapid growth,abundant angiogenesis,and early distant metastasis that accounts for about 15%of lung *** the wide application of low-dose computed tomography screening in recent years,the incidence of early limited-stage SCLC has increased dramatically.